30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective

Emerging evidence from the numerous clinical trials involving cytokine-induced killer (CIK) cell therapy suggests that its optimization in combination with other contemporary cancer therapies in a complementary manner (rather than as competition) will be a key to combat cancer.

Saved in:

Bibliographic Details
Published in:	Journal of experimental & clinical cancer research Vol. 40; no. 1; p. 388
Main Authors:	Sharma, Amit, Schmidt-Wolf, Ingo G H
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 09-12-2021 BioMed Central BMC
Subjects:	Cancer Cancer therapies Care and treatment Cell- and Tissue-Based Therapy - methods Clinical trials Cytokine-induced killer (CIK) cell therapy Cytokine-Induced Killer Cells - metabolism Cytokines Cytotoxicity Dendritic cells Epigenetics Graft versus host disease Humans Immunotherapies Immunotherapy Immunotherapy - methods Monoclonal antibodies Neoplasms - drug therapy Time Factors Tumors Immunotherapies Cytokine-induced killer (CIK) cell therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Emerging evidence from the numerous clinical trials involving cytokine-induced killer (CIK) cell therapy suggests that its optimization in combination with other contemporary cancer therapies in a complementary manner (rather than as competition) will be a key to combat cancer.
Bibliography:	SourceType-Other Sources-1 content type line 63 ObjectType-Editorial-2 ObjectType-Commentary-1
ISSN:	1756-9966 0392-9078 1756-9966
DOI:	10.1186/s13046-021-02184-2